KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Johnson & Johnson (JNJ) Finished Goods (2012 - 2018)

Johnson & Johnson recorded quarterly Finished Goods of $5.4 billion in Q4 2018, down 2.08% quarter-over-quarter from $5.5 billion in Q3 2018, and up 1.28% year-over-year from $5.3 billion in Q4 2017.

Johnson & Johnson's Finished Goods history runs 6 years deep, the most recent figure standing at $5.4 billion for Q4 2018.

  • In Q4 2018, Finished Goods rose 1.28% year-over-year to $5.4 billion; the TTM figure through Dec 2018 stood at $5.4 billion (up 1.28% YoY), while the FY2018 annual figure was $5.4 billion, up 1.28% from the prior year.
  • Finished Goods came in at $5.4 billion for Q4 2018 at Johnson & Johnson, down from $5.5 billion in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $5.5 billion in Q3 2018 to a low of $4.5 billion in Q4 2014.
  • A 4-year average of $5.1 billion and a median of $5.3 billion in 2017 frame the typical range for Finished Goods.
  • Across the five-year window, Finished Goods rose 11.55% in 2014 and grew 1.28% in 2018, its largest moves.
  • Johnson & Johnson's Finished Goods stood at $4.5 billion in 2014, then rose by 8.14% to $4.9 billion in 2016, then increased by 8.86% to $5.3 billion in 2017, then gained by 1.28% to $5.4 billion in 2018.
  • According to Business Quant data, Finished Goods over the past three periods registered $5.4 billion, $5.5 billion, and $5.4 billion for Q4 2018, Q3 2018, and Q3 2018 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 30, 2018 5.38 Bn
Sep 30, 2018 5.49 Bn
Jul 1, 2018 5.36 Bn
Dec 31, 2017 5.31 Bn
Jan 1, 2017 5.01 Bn
Jan 3, 2016 4.88 Bn
Dec 28, 2014 4.51 Bn
Dec 29, 2013 4.04 Bn
Dec 30, 2012 3.82 Bn
Jan 1, 2012 3.44 Bn